Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 173 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Prostate Cancer Phase2 Japan

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma Phase1 France
Germany
Israel
Italy
Portugal
Spain
United Kingdom
United States
View all

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer Germany

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

C3G Phase3 Brazil
Canada
China
France
Germany
Greece
India
Israel
Italy
Japan
Netherlands
Spain
Switzerland
Turkey (Türkiye)
United Kingdom
United States
View all

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis Germany

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Systemic Lupus Erythematosus Phase3 Argentina
Brazil
Bulgaria
Canada
China
Colombia
Czechia
Guatemala
Hungary
Israel
Japan
Poland
Portugal
Singapore
Slovakia
South Africa
Spain
Thailand
Turkey (Türkiye)
United States
View all

A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Asthma South Korea

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC) Phase3 Argentina
Australia
Belgium
Brazil
Canada
China
Czechia
France
Germany
Greece
Hungary
Israel
Italy
Japan
Malaysia
Mexico
Netherlands
Puerto Rico
Singapore
Slovakia
Spain
Switzerland
Taiwan
United Kingdom
United States
View all

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Systemic Lupus Erythematosus Phase3 Argentina
Australia
Chile
Colombia
France
Germany
India
Italy
Malaysia
Mexico
Romania
South Korea
Taiwan
United Kingdom
United States
View all

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia

HR+HER2- Advanced Breast Cancer Russia